2009
DOI: 10.1111/j.1349-7006.2009.01185.x
|View full text |Cite
|
Sign up to set email alerts
|

Involvement of G‐patch domain containing 2 overexpression in breast carcinogenesis

Abstract: Through analysis of the detailed genome-wide gene expression profiles of 81 breast tumors, we identified a novel gene, G-patch domain containing 2 (GPATCH2), that was overexpressed in the great majority of breast cancer cases. Treatment of breast cancer cells MCF-7 and T47D with siRNA against GPATCH2 effectively suppressed its expression, and resulted in the growth suppression of cancer cells, suggesting its essential role in breast cancer cell growth. We found an interaction of GPATCH2 protein with hPrp43, an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
55
0
1

Year Published

2010
2010
2022
2022

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 45 publications
(58 citation statements)
references
References 24 publications
2
55
0
1
Order By: Relevance
“…GPAT2 silencing also diminished cell proliferation of HCT116 cells and both murine and human GPAT2 overexpression increased cell proliferation. These results agree with experiments reporting either siRNA-mediated silencing or overexpression of specific CT genes, which demonstrate causality between CT gene expression and growth phenotype [21]–[25]. The dramatic reduction of the MDA-MB-231 tumor phenotype by GPAT2 silencing was also evident in vivo , because knocked down cells were unable to generate tumor xenografts in nude mice.…”
Section: Discussionsupporting
confidence: 90%
“…GPAT2 silencing also diminished cell proliferation of HCT116 cells and both murine and human GPAT2 overexpression increased cell proliferation. These results agree with experiments reporting either siRNA-mediated silencing or overexpression of specific CT genes, which demonstrate causality between CT gene expression and growth phenotype [21]–[25]. The dramatic reduction of the MDA-MB-231 tumor phenotype by GPAT2 silencing was also evident in vivo , because knocked down cells were unable to generate tumor xenografts in nude mice.…”
Section: Discussionsupporting
confidence: 90%
“…Through the genome-wide expression analysis of a large number of microdissected clinical cancer materials, we have identified dozens of genes that function as oncogenes in the process of development and/or progression of breast cancer (10)(11)(12)(13)(14)(15)(16)(17), bladder cancer (18,19), synovial sarcoma (20,21), testicular seminoma (22), and renal cell carcinoma (23,24). Such molecules are considered to be candidate molecular targets for development of new therapeutic modalities.…”
Section: Introductionmentioning
confidence: 99%
“…Hence, development of novel moleculartargeted drugs for breast cancer with higher efficacy and low risk of adverse reactions is essentially important to improve clinical management. Toward development of such therapeutic agents, we had analyzed the genome-wide gene expression profile of 81 breast cancers as well as 29 normal human organs using cDNA microarray and have reported several novel target candidates for breast cancer therapy (3)(4)(5)(6)(7)(8)(9)(10)(11). In this article, we describe the identification and characterization of UDP-N-acetyl-α-D-galactosamine (GalNAc):polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6), which was upregulated in a great majority of breast cancer cases.…”
Section: Introductionmentioning
confidence: 99%